Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee

  • Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Markt vandaag Koersen Forum Premium IEX Expert
Home  /  Forum  /  Koffiekamer  /  Nanobiotix met haar NBTXR3 richting €80,- in 2014 ? (Heden €17,-)

Koffiekamer« Terug naar discussie overzicht

Nanobiotix met haar NBTXR3 richting €80,- in 2014 ? (Heden €17,-)

Volgen
524 Posts
Pagina: «« 1 ... 22 23 24 25 26 27 »» | Laatste | Omlaag ↓
  1. Omnius 7 maart 2017 09:52
    Ben erg benieuwd naar de resultaten, maar ze claimen dus in meerdere kankersoorten een verbetering zowel bij bestraling, maar dus ook bij chemo...

    Hopelijk dit jaar CE goedkeuring:
    NBTXR3 first market authorization filing
    The Company filed for certification of NBTXR3 in August 2016 based on the current level of clinical and scientific evidence. LNE/G-MED, the French notified body, has given guidance that the review of results for a potential CE mark is expected in 2017.
  2. Omnius 24 maart 2017 09:25
    www.nanobiotix.com/download/news_en/2...

    NANOBIOTIX: THE INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDS
    THE CONTINUATION OF THE ONGOING PHASE II/III TRIAL OF NBTXR3 IN SOFT TISSUE SARCOMA
    Paris, France and Cambridge, Massachusetts, USA, March 23, 2017 – NANOBIOTIX (Euronext: NANO – ISIN:
    FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the local treatment
    of cancer, today announced that the Independent Data Monitoring Committee (IDMC) has completed the interim
    evaluation of the Phase II/III trial results (Act.In.Sarc) of NBTXR3 in soft tissue sarcoma.
    The interim evaluation was based on an analysis of the results of two-thirds of the patients included in the Phase
    II/III study – 104 patients were analyzed out of a total of 156. Based on the safety and available efficacy data, the
    IDMC has recommended the continuation of the Phase II/III trial of NBTXR3 in soft tissue sarcoma.
    “The IDMC’s recommendation to continue the ongoing phase II/III trial of NBTXR3 is very positive news for soft
    tissue sarcoma patients, and an important milestone in NBTXR3’s clinical development.” said Elsa Borghi,
    Nanobiotix’s Chief Medical Officer “Now, we look forward to seeing the full data analysis” she added.
    The pivotal international Phase II/III study in soft tissue sarcoma was launched in Europe and Asia in October
    2014 and aims to evaluate the safety and the efficacy of NBTXR3, a first in-class radio enhancer that could
    potentially target most solid tumors. The Phase II/III study is a prospective, randomized, multi-center, open label
    and active controlled two-armed study of 156 patients with locally advanced soft tissue sarcoma. The primary
    endpoint is the complete pathological response rate. The secondary endpoints are the objective response rate
    (ORR) by imaging (MRI); the evaluation of the safety profile in term of clinical and laboratory adverse events; the
    tumor volume changes; the resection margins and the limb amputation rate.
    The IDMC is an international independent body of experts made up of scientists, statisticians and practicing
    physicians. Specifically, it was chartered to review and ensure: i) the data related to the primary endpoint, ii) the
    safety of all patients enrolled in the study, (iii) the quality of the data collected, and (iv) the continued scientific
    validity of the study design on two thirds of the patients treated.
    The completion of recruitment for the Act.in.Sarc trial is planned by the end of Q2 2017. The full data analysis,
    except for long-term follow-up, is expected to be available at the end of 2017.
    Based on the positive recommendation from the IDMC, the Company will communicate, over the coming weeks,
    its overall plan to move forward
  6. Omnius 31 maart 2017 13:36
    quote:

    Vendoefel schreef op 31 maart 2017 11:59:

    www.leparisien.fr/high-tech/sante-nan...

    door de google translate gehaald:
    Health: Nanobiotix, the little Gaul who attacks cancer
    > High-Tech | Daniel Rosenweg | 31 March 2017, 10:20 |0
    Laurent Levy, founding president of Nanobiotix, is satisfied: the first results of the tests of its medical device NanoXray are very positive and pave the way for a commercialization in 2018.LP / FRÉDÉRIC DUGIT
    Daniel Rosenweg
    High-Tech Laurent Lévy Nanobiotix innovation health medicine
    SHOPPING
    With iGraal

    Save on all your High Tech purchases
    A pioneer in the use of nanoparticles in medicine, this young shoot develops a potentially revolutionary treatment of malignant tumors.

    " Developing in France, yes, it's easy," says Laurent Lévy, founding president of Nanobiotix . Radiating the world, on the other hand ... However, the Parisian biotech that it directs since its creation in 2003 is about to upset the uses in the treatment of cancerous tumors. After fourteen years of innovative work, 2017 presents itself as the pivotal year that should see the French nugget open.

    The first results of the tests of its medical device NanoXray, which greatly improves the effectiveness of radiotherapy against cancer, fell on March 23: "They are very positive," enthuses Laurent Lévy, which opens The way to a commercialization likely from 2018. Other results, among the 17 clinical trials in progress, are expected in the coming months. If all goes well, they should allow to multiply the therapeutic indications of this innovation whose authorization of sale is expected for the second half of 2017.

    Then we will have to discuss with the authorities the level of reimbursement. As a mass technology, a potential market of several million patients in the world could open up.

    100 million euros raised in 14 years

    In the meantime, the start-up (it generated € 1.5 million in sales in 2016, but not yet profits), which employs 70 people at its Paris headquarters, and about 20 others in its An American subsidiary located near Boston, will hire. After having already doubled its workforce in two years, "we must now prepare market access," justifies Laurent Levy.

    To achieve this, the biotech has had to rely on various financing. Among the first financiers, BPI, the public investment bank , paid grants and repayable advances. Then, in 2012, Nanobiotix entered the stock market, established partnerships while remaining independent. In fourteen years, the small company raised € 100 million, which enabled it to finance research, clinical trials and the filing of several hundred international patents.

    "In France, we focus on projects"

    Innovating in France, "it's easy," says Laurent Lévy. "France has changed in the last fifteen years: the ecosystem, the entrepreneurial spirit are not the same and do not forget, we also have the research tax credit (CIR) and credit Tax for competitiveness and employment (CICE). "And then, adds the doctor in nanotechnology," we have in France something that exists nowhere else: the quality of people. Here, they are committed to projects, to the company, and they are faithful when, in the United States, companies are confronted with an incessant staff renewal. "

    President, what would he do? "I would put entrepreneurs at the head of the country, because entrepreneurs look ahead and go," he smiles. More concretely, "I would remove all taxes on innovative companies. Zero tax, including for those who invest in these companies. It's the best way to grow faster and get quicker work. "


    Crystals enhance the effectiveness of spokes



    Today, in the case of a cancerous tumor , the tissues are treated by chemotherapy or radiotherapy in order to reduce its size and then intervene in surgery if the tumor has not disappeared. More than seven million patients worldwide are treated each year by radiotherapy , a radiation that targets the tumor but makes significant damage to the healthy tissues it passes through.

    The innovation of Nanobiotix consists in intervening before the radiotherapy by injection of a product, denominated NTBX3, containing kinds of microscopic crystals cut in such a way that they will amplify up to nine times the energy of the ray. This reduces either the number of sessions or the intensity of the rays. Injected directly into the tumor, these crystals cling to the malignant cells and arouse a kind of local mini-explosion when they are touched by the ray. As the tumor decreases, the crystals remain intact and hooked so that their density increases during the sessions of radiotherapy, constantly increasing the effectiveness of the treatment. Then, these invisible crystals remain in the body without any side effects.

    If the approach is revolutionary, the technology used is a major innovation since it uses nanoparticles, of which Nanobiotix is ??a pioneer. To get an idea: it takes 3000 nanoparticles to have the diameter of a hair. Nanobiotix has therefore developed a patented technology to aggregate hafnium oxide nanoparticles, a molecule capable of clinging to malignant cells by giving them a spherical shape. "This device can treat virtually all solid tumors," says Laurent Lévy, CEO of Nanobiotix. It dramatically increases patient operability. "
  9. [verwijderd] 12 april 2017 09:04
    A Look at the Technicals For Nanobiotix SA (ENXTPA:NANO)

    April 12, 2017
    Investors may be interested in viewing the Gross Margin score on shares of Nanobiotix SA (ENXTPA:NANO). The name currently has a score of 63.00000. This score is derived from the Gross Margin (Marx) stability and growth over the previous eight years. The Gross Margin score lands on a scale from 1 to 100 where a score of 1 would be considered positive, and a score of 100 would be seen as negative. The low score of 63.00000 for Nanobiotix SA indicates a top score for stability and growth.

    Checking in on some valuation rankings, Nanobiotix SA (ENXTPA:NANO) has a Value Composite score of 91. Developed by James O’Shaughnessy, the VC score uses five valuation ratios. These ratios are price to earnings, price to cash flow, EBITDA to EV, price to book value, and price to sales. The VC is displayed as a number between 1 and 100. In general, a company with a score closer to 0 would be seen as undervalued, and a score closer to 100 would indicate an overvalued company. Adding a sixth ratio, shareholder yield, we can view the Value Composite 2 score which is currently sitting at 92.

    After a recent scan, we can see that Nanobiotix SA (ENXTPA:NANO) has a Shareholder Yield of -0.100860 and a Shareholder Yield (Mebane Faber) of 0.21020. The first value is calculated by adding the dividend yield to the percentage of repurchased shares. The second value adds in the net debt repaid yield to the calculation. Shareholder yield has the ability to show how much money the firm is giving back to shareholders via a few different avenues. Companies may issue new shares and buy back their own shares. This may occur at the same time. Investors may also use shareholder yield to gauge a baseline rate of return.

    At the time of writing, Nanobiotix SA (ENXTPA:NANO) has a Piotroski F-Score of 2. The F-Score may help discover companies with strengthening balance sheets. The score may also be used to spot the weak performers. Joseph Piotroski developed the F-Score which employs nine different variables based on the company financial statement. A single point is assigned to each test that a stock passes. Typically, a stock scoring an 8 or 9 would be seen as strong. On the other end, a stock with a score from 0-2 would be viewed as weak.

    Nanobiotix SA (ENXTPA:NANO) has a current ERP5 Rank of 14346 . The ERP5 Rank may assist investors with spotting companies that are undervalued. This ranking uses four ratios. These ratios are Earnings Yield, ROIC, Price to Book, and 5 year average ROIC. When looking at the ERP5 ranking, it is generally considered the lower the value, the better.

    Shifting gears, we can see that Nanobiotix SA (ENXTPA:NANO) has a Q.i. Value of 76.00000. The Q.i. Value ranks companies using four ratios. These ratios consist of EBITDA Yield, FCF Yield, Liquidity, and Earnings Yield. The purpose of the Q.i. Value is to help identify companies that are the most undervalued. Typically, the lower the value, the more undervalued the company tends to be.

  15. Omnius 4 augustus 2017 13:14
    www.proactiveinvestors.co.uk/companie...

    anobiotix technology has "blockbuster potential", according to American investment bank
    Share
    11:35 02 Aug 2017
    Nanoparticles with mega potential - that’s how the biotech team at American investment bank described the company's technology
    Patient undergoing radiotherapy
    The breakthrough amplifies the effect of radiotherapy
    Nanoparticles with mega potential - that’s how the biotech team at American investment bank Jefferies described Nanobiotix SA (EPA:NANO), which has developed a unique method of amplifying radio-therapy.

    Jefferies Wednesday initiated coverage of stock in the company with a ‘buy’ rating and €26 a share price target. That’s 32% above the current price of €19.66.

    The company has developed NBTXR3, which is injected directly into solid tumours to amplify the effects of tumour shrinking treatment.

    It has already demonstrated success tackling soft tissue sarcoma, a cancer that affects muscle, fat and blood vessels.

    Analyst Peter Welford believes the treatment has “blockbuster potential” if is widely adopted.

    “As a one-time treatment that is fully compatible with standard radiotherapy protocols, NBTXR3 could be used in around 60% of radiotherapy-treated cancers,” he said.

    The analyst estimates worldwide peak sales for use in soft tissue sarcoma (STS) could be in the order of US$175mln, while head and neck cancer is a far bigger market for Nanobiotix at US$550mln a year.

    Other uses...
    However, the product could generate US$1.4bn a year for the business if it is more widely adopted, Welford reckons.

    The current valuation only takes into account NBTXR3’s use in STS and head and neck cancer.

    “NBTXR3 could also act as an in situ vaccine with radiotherapy to aid transforming tumours from ‘cold’ to ‘hot’ with highly immunogenic targets, suggesting a potentially lucrative combo with immuno-oncology agents,” the analyst pointed out.
  19. Bioteg71 6 juni 2018 16:10
    quote:

    Omnius schreef op 6 juni 2018 09:47:

    Nanobiotix SA (NANO.PA)
    Paris - Paris Delayed Price. Currency in EUR
    8.45-1.55 (-15.50%)
    As of 9:31AM CEST. Market open.

    Wordt flink gedumpt laatste dagen, maar ik kan niet direct nieuws vinden. Iemand?
    Ik ook niet, wel heel vreemd koersverloop. Nu groot herstel met flink volume
524 Posts
Pagina: «« 1 ... 22 23 24 25 26 27 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
EBUSCO HOLDING 1,006 +0,08 +8,11%
JDE PEET'S 21,060 +0,82 +4,05%
SBM Offshore 16,850 +0,45 +2,74%
TomTom 4,960 +0,13 +2,61%
PostNL 1,224 +0,03 +2,60%
Avantium 2,530 +0,06 +2,43%
Pharming 0,717 +0,02 +2,14%
AMG Critical Materials N.V. 14,330 +0,28 +1,99%
EXOR NV 93,850 +1,40 +1,51%
SIGNIFY NV 21,100 +0,30 +1,44%
INPOST 15,510 +0,21 +1,37%
JUST EAT TAKEAWAY 12,825 +0,17 +1,34%
NN Group 45,600 +0,60 +1,33%
ASML 799,300 +9,80 +1,24%
Sif Holding 12,140 +0,14 +1,17%
WDP 24,860 +0,28 +1,14%
ASR Nederland 44,450 +0,49 +1,11%
Aegon 5,658 +0,06 +1,04%
Kendrion 11,760 +0,12 +1,03%
Fugro 22,240 +0,22 +1,00%
Sligro 12,200 +0,10 +0,83%
Vopak 40,220 +0,30 +0,75%
Fagron 19,120 +0,14 +0,74%
Basic-Fit 21,900 +0,16 +0,74%
Flow Traders 17,420 +0,12 +0,69%
AMX 871,63 +5,85 +0,68%
B&S Group SA 4,620 +0,03 +0,65%
Philips Koninklijke 25,980 +0,16 +0,62%
Van Lanschot Kempen NV 38,950 +0,20 +0,52%
ASCX 1.192,01 +6,01 +0,51%
ASMI 581,600 +2,60 +0,45%
Vastned 23,800 +0,10 +0,42%
Wolters Kluwer 151,300 +0,60 +0,40%
BESI 116,100 +0,45 +0,39%
Heineken 79,760 +0,30 +0,38%
ADYEN NV 1.138,200 +3,80 +0,33%
RELX 41,360 +0,10 +0,24%
SHELL PLC 32,975 +0,08 +0,23%
ACOMO 17,680 +0,04 +0,23%
Ahold Delhaize 29,820 +0,06 +0,20%
UMG 22,150 +0,04 +0,18%
Accsys 0,609 +0,00 +0,16%
AEX 890,24 +1,33 +0,15%
IMCD 138,000 +0,20 +0,15%
Wereldhave 13,980 +0,02 +0,14%
Air France-KLM 7,610 +0,01 +0,11%
Corbion 20,900 +0,02 +0,10%
ALLFUNDS GROUP 5,250 +0,00 +0,10%
Arcadis 62,900 +0,05 +0,08%
ING 15,340 +0,01 +0,07%
BAM 3,562 +0,00 +0,06%
AZERION 1,498 0,00 0,00%
HEIJMANS KON 25,450 0,00 0,00%
NSI 20,200 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
ABN AMRO BANK N.V. 14,825 -0,54 -3,51%
PROSUS 32,445 -0,77 -2,30%
Alfen N.V. 14,930 -0,30 -1,97%
CM.COM 6,840 -0,09 -1,30%
NX FILTRATION 5,010 -0,06 -1,18%
DSM FIRMENICH AG 116,300 -1,30 -1,11%
Nedap N.V. 56,200 -0,60 -1,06%
Galapagos 22,120 -0,22 -0,98%
OCI 26,260 -0,24 -0,91%
TKH 36,320 -0,30 -0,82%
RENEWI 7,760 -0,06 -0,77%
CTP 16,140 -0,08 -0,49%
Akzo Nobel 53,120 -0,26 -0,49%
Eurocommercial Properties 23,200 -0,10 -0,43%
RANDSTAD NV 41,460 -0,17 -0,41%
AALBERTS NV 33,320 -0,12 -0,36%
ForFarmers 2,795 -0,01 -0,36%
Aperam 24,900 -0,08 -0,32%
ArcelorMittal 19,715 -0,05 -0,25%
FASTNED 16,440 -0,04 -0,24%
Brunel 9,280 -0,02 -0,22%
THEON INTERNAT 11,260 -0,02 -0,18%
KPN 3,588 0,00 -0,06%
UNILEVER PLC 55,280 -0,02 -0,04%
vlag naam koers verschil relatief verschil
AEX 890,24 +1,33 +0,15%
AEX GR 3.470,04 +6,25 +0,18%
Germany40^ 17.901,60 +16,00 +0,09%
FTSE 100 8.281,05 +45,82 +0,56%
EURO50 4.732,38 +26,24 +0,56%
US30^ 40.002,50 0,00 0,00%
Nasd100^ 19.020,80 0,00 0,00%
US500^ 5.453,75 0,00 0,00%
Japan225^ 36.282,50 0,00 0,00%
VD-NEW 15,47 -1,47 -8,69%
#/^ Index indications calculated real time, zie disclaimer